San Jose, California (PRWEB) July 10, 2012
Follow us on LinkedIn – Prenatal testing has changed the experiences of pregnancy since its availability. The tests add a new dimension to the usual enthusiasm and expectations that pregnancy brings to a couple by providing them with the information on the health of the fetus. Technologies such as screening methods including ultrasound and maternal serum screening along with invasive diagnostic tests have been used to portray the status of the fetal health much before the baby is actually born. Despite the use of these tests for several years, they continue to be marred with certain limitations. Ultrasound is useful in detecting only physical abnormalities, while serum screening tests provide a probability picture without confirming the detections. On the other hand, although invasive tests have been more accurate in diagnosing fetal malformations, they are fraught with procedural risks. As a result, the search for novel technologies continues to remain on the agenda of diagnostics companies. The non-invasive prenatal diagnostic approach is the latest in prenatal diagnosis space, which promises to wipe out existing gaps in diagnosis. The technology is expected to address most unmet needs in the area of prenatal diagnosis.
Prenatal diagnosis or diagnosis of the fetus enables diagnosis of several inheritable disorders in the fetus as well as other conditions. The technique is used most commonly in detecting genetic mutations, chromosomal abnormalities and neural tube defects. Although, prenatal testing can be used for detecting presence of a wide range of fetal abnormalities or conditions, detection of chromosomal abnormalities is the lead application. Within the chromosomal abnormalities, Down’s syndrome is the most common abnormality tested through prenatal diagnostic tests. This is so due to the fact that the syndrome is highly correlated to the age of the mother.
Non-Invasive Prenatal Diagnosis (NIPD) is an area receiving remarkable interest from several scientists and companies worldwide within the prenatal testing domain. These tests are used for diagnosis of fetal abnormalities in a non-invasive manner, as opposed to the current gold-standard invasive diagnostic techniques such as Chorionic Villus Sampling (CVS) and Amniocentesis. In addition to eliminating all known procedural risks associated with invasive techniques, NIPD also helps in detection of fetal abnormalities at the earliest. The existing non-invasive screening techniques are not definitive in diagnosis, and usually necessitate further use of invasive techniques when fetal abnormalities are diagnosed during these tests. Lower specificity and sensitivity act as major hurdles to adoption of these screening tests. Ultrasound remains a key component of screening tests, being used profusely in conjunction with blood tests for identifying fetal abnormalities. NIPD is certainly a revolutionary approach in prenatal testing. The tests endeavor to achieve accuracy levels of invasive diagnostic testing in a non-invasive manner, and at relatively early stages of pregnancy, in addition to completely avoid low-accuracy prenatal screening tests.
The inherent advantage of eliminating risks of procedure-led miscarriages and uncertainty in existing marker-based screening tests offers a tremendous market potential for non-invasive prenatal diagnostics. The drive towards early diagnosis of fetal abnormalities and to reduce dependence on risky invasive procedures is garnering significant momentum in the development of this area. This in turn is expected to drive growth in demand for these techniques in the following years. The technique is amply supported by use of molecular assays and next generation sequencing techniques, all aimed at isolation of fetal DNA from maternal blood samples and analyzing them further for presence of abnormalities in the fetal genetic material. The market potential for these tests is huge with over 6.0 million pregnancies each year in the US alone. Growth in adoption of these techniques, however, depends upon the sensitivity and specificity aspects of these tests, scientific advancements, their cost-effectiveness, and resolving other issues surrounding the approach. With higher specificities demonstrated by some of the tests launched in the market, the future for NIPD tests appears bright, driving the overall prenatal diagnostics market.
The US represents the largest regional market for prenatal diagnostics worldwide, as stated by the new market research report on Prenatal Diagnostics. Europe represents the second largest regional market worldwide. However, growth in the global market is projected to be driven by emerging economies in Asia-Pacific and Latin America.
Major players profiled in the report include Abbott Molecular, Angle Plc., Hologic Inc., PerkinElmer, Inc., Ravgen, Inc., Sequenom, Inc., Sequenom Center for Molecular Medicine, LLC, and TrovaGene, Inc.
The research report titled “Prenatal Diagnostics: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides comprehensive market overview, trends & issues, recent industry activity and profiles of market players worldwide. Analysis and overview is provided for the years 2009 through 2018, for major geographic markets, such as the US, Canada, Japan, Europe and Rest of World. Market analytics are provided in terms of Annual revenues in US$ Million.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/